West Pharmaceutical Services, Inc.

Case Overview
60 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 07/07/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: West Pharmaceutical Services, Inc. |
Court: | Court: Eastern District of Pennsylvania |
Case Number: | Case Number: 2:25cv02285 |
Class Period: | Class Period: 02/16/2023 - 02/12/2025 |
Ticker: | Ticker: WST |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania on behalf of those who acquired West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE:WST) securities during the period from February 16, 2023, through February 12, 2025 (“the Class Period”). Investors have until July 7, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On February 13, 2025, when West issued extremely weak 2025 revenue and earning forecasts. West attributed the disappointing guidance n part of CM headwinds, including the loss of two major CGM customers that had begun transitioning to in-house manufacturing of next generation devices after West “made the decision to not participate going forward as our financial thresholds cannot be achieved.” West also revealed that its SmartDose wearable injector devices would be “margin dilutive” in 2025 and that it would be “taking steps to improve [its SmartDose] economics, and all options are on the table.” On this news, the price of West shares declined by $123.17 per share, or approximately 38%, from $322.28 per share on February 12, 2025, to close at $199.11 on February 13, 2025.
The complaint alleges that defendants, throughout the Class Period, failed to disclose that: (1) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin HVP portfolio; (2) West’s SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company’s profit margins due to operational inefficiencies; and (3) these margin pressures created the risk of costly restructuring activities, including the Company’s exit from continuous glucose monitoring (“CGM”) contracts with long-standing customers.
On February 13, 2025, when West issued extremely weak 2025 revenue and earning forecasts. West attributed the disappointing guidance n part of CM headwinds, including the loss of two major CGM customers that had begun transitioning to in-house manufacturing of next generation devices after West “made the decision to not participate going forward as our financial thresholds cannot be achieved.” West also revealed that its SmartDose wearable injector devices would be “margin dilutive” in 2025 and that it would be “taking steps to improve [its SmartDose] economics, and all options are on the table.” On this news, the price of West shares declined by $123.17 per share, or approximately 38%, from $322.28 per share on February 12, 2025, to close at $199.11 on February 13, 2025.
The complaint alleges that defendants, throughout the Class Period, failed to disclose that: (1) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin HVP portfolio; (2) West’s SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company’s profit margins due to operational inefficiencies; and (3) these margin pressures created the risk of costly restructuring activities, including the Company’s exit from continuous glucose monitoring (“CGM”) contracts with long-standing customers.